Healthcare provider profile · identity verified

Andilay Rivero

Nurse Practitioner · HIALEAH, FL · NPI 1952178881

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Methocarbamol	Methocarbamol	211	184
Gabapentin	Gabapentin	167	96
Benzonatate	Benzonatate	155	141
Atorvastatin Calcium	Atorvastatin Calcium	142	115
Albuterol Sulfate Hfa	Albuterol Sulfate	128	71
Vitamin D2	Ergocalciferol (Vitamin D2)	128	67
Azithromycin	Azithromycin	113	109
Levothyroxine Sodium	Levothyroxine Sodium	79	48
Losartan Potassium	Losartan Potassium	77	64
Lisinopril	Lisinopril	76	51
Metformin Hcl	Metformin Hcl	76	48
Prednisone	Prednisone	71	64
Temazepam	Temazepam	66	33
Pantoprazole Sodium	Pantoprazole Sodium	65	48
Chlordiazepoxide Hcl	Chlordiazepoxide Hcl	58	32
Memantine Hcl	Memantine Hcl	56	35
Rosuvastatin Calcium	Rosuvastatin Calcium	55	41
Donepezil Hcl	Donepezil Hcl	54	34
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	46	26
Meclizine Hcl	Meclizine Hcl	45	39
Amlodipine Besylate	Amlodipine Besylate	44	40
Montelukast Sodium	Montelukast Sodium	44	25
Diclofenac Potassium	Diclofenac Potassium	42	38
Escitalopram Oxalate	Escitalopram Oxalate	39	26
Metoprolol Succinate	Metoprolol Succinate	38	29
Hydrochlorothiazide	Hydrochlorothiazide	36	33
Omeprazole	Omeprazole	36	24
Sildenafil Citrate	Sildenafil Citrate	36	26
Folic Acid	Folic Acid	35	20
Glipizide	Glipizide	34	26
Pregabalin	Pregabalin	33	13
Atrovent Hfa	Ipratropium Bromide	31	24
Clobetasol Propionate	Clobetasol Propionate	30	16
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	30	29
Famotidine	Famotidine	29	19
Clopidogrel	Clopidogrel Bisulfate	28	19
Furosemide	Furosemide	27	21
Alprazolam	Alprazolam	26	17
Carvedilol	Carvedilol	26	17
Cephalexin	Cephalexin	26	26
Clonazepam	Clonazepam	26	suppressed
Nifedipine Er	Nifedipine	26	19
Tamsulosin Hcl	Tamsulosin Hcl	26	20
Glimepiride	Glimepiride	25	12
Trueplus Pen Needle	Pen Needle, Diabetic	25	12
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	24	19
Dapagliflozin	Dapagliflozin Propanediol	23	12
Latanoprost	Latanoprost	23	15
Metoprolol Tartrate	Metoprolol Tartrate	23	22
Tadalafil	Tadalafil	23	suppressed
Cefuroxime	Cefuroxime Axetil	22	22
Ciprofloxacin Hcl	Ciprofloxacin Hcl	22	22
Mirtazapine	Mirtazapine	22	17
Tramadol Hcl	Tramadol Hcl	21	18
Alendronate Sodium	Alendronate Sodium	20	14
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	20	13
Fenofibrate	Fenofibrate	20	15
Mupirocin	Mupirocin	20	19
Levofloxacin	Levofloxacin	19	19
Simvastatin	Simvastatin	19	14
Glipizide Er	Glipizide	18	11
Hydralazine Hcl	Hydralazine Hcl	18	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	18	suppressed
Metformin Hcl Er	Metformin Hcl	18	16
Fluticasone Propionate	Fluticasone Propionate	17	13
Dicyclomine Hcl	Dicyclomine Hcl	15	14
Lubiprostone	Lubiprostone	15	12
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	14	suppressed
Mometasone Furoate	Mometasone Furoate	14	12
Quetiapine Fumarate	Quetiapine Fumarate	14	suppressed
Xarelto	Rivaroxaban	14	13
Citalopram Hbr	Citalopram Hydrobromide	13	suppressed
Trazodone Hcl	Trazodone Hcl	13	11
Ammonium Lactate	Ammonium Lactate	12	suppressed
Metronidazole	Metronidazole	12	12
Neomycin-Polymyxin-Hydrocort	Neomycin/Polymyxin B/Hydrocort	12	12
Novolin 70-30	Insulin Nph Hum/Reg Insulin Hm	12	suppressed
Ondansetron Hcl	Ondansetron Hcl	12	12
Proctozone-Hc	Hydrocortisone	12	suppressed
Ibuprofen	Ibuprofen	11	suppressed
Labetalol Hcl	Labetalol Hcl	11	suppressed
Levalbuterol Tartrate Hfa	Levalbuterol Tartrate	11	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	11	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error